$MEDI.NE - Clinically Established Psychedelic Company If you’re interested in getting into the psychedelic space, then KetamineOne should be one on your watchlist. They’re an already established clinical psychedelic company utilizing tech and data to improve their patient experiences.
- Using wearables to track the pre, during, and post-treatment vitals of patients to build data for patient experience by measuring physical signals/responses to the treatments
- Already has 16 clinics with 3 under LOI
- $3.5M in 2020 revenue and $6M expected for 2021
It is estimated that 1 in 5 Americans were living with a mental illness or addiction. The anxiety disorder/depression treatment market is massive ($238B, to be more accurate). $MEDI.NE is rapidly breaking into this market by focusing on patient experiences (increased return/repeat patients) and clinic retrofits, openings, and acquisitions.
The psychedelic industry is estimated to be worth $2.8B, and by 2028, Data Bridge Market Research sees the market growing with a CAGR of 13.3%, reaching $7.6B by 2028. With all the research and current treatments going into the space, this growth is why everyone should keep at least one psychedelic-focused stock in their portfolio. $MEDI.NE is a stable and safe investment due to being already clinically established with the ability to administer psychedelic-assisted therapy for its patients.
https://www.globenewswire.com/news-release/2021/07/14/2263133/0/en/Psychedelic-Drugs-Market-CAGR-at-13-3-with-Analysis-of-Growing-Technology-Trends-Industry-Research-Future-Growth-and-Size-Projection-by-2028.html
Currently, the market cap is at $184M, and I expect a lot more growth to come shortly.
Read more about $MEDI here: https://www.ketamine.one/investor-relations